Hemispherian, an Oslo, Norway-based preclinical pharmaceutical company, raised $2.9M in the first tranche of a Series A funding.
The round was led by Meneldor, with participation from Kistefos AS, Kvantia AS, and Steven Powell.
The company intends to use the funds to support its drug development activities, expand its preclinical pipeline and advance its lead therapeutic compounds towards clinical development.
Led by CEO Zeno Albisser, Hemispherian is a pharmaceutical company focused on developing a novel class of small molecule drugs called GLIX. GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company’s lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1.
FinSMEs
24/11/2022